Ocuphire Pharma

About:

Ocuphire Pharma, a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.

Website: https://www.ocuphire.com/

Top Investors: Biosciences Research and Commercialization Center (BRCC), National Eye Institute, BELLE Capital, Altium Capital, Lincoln Park Capital Fund

Description:

Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.